Identification of PIK3C3 promoter variant associated with bipolar disorder and schizophrenia

Psychiatric Clinic, First Medical Faculty, Charles University, Prague, Czech Republic.
Biological Psychiatry (Impact Factor: 10.26). 06/2004; 55(10):981-8. DOI: 10.1016/j.biopsych.2004.01.014
Source: PubMed


Genes involved in phosphoinositide (PI) lipid metabolism are excellent candidates to consider in the pathogenesis of bipolar disorder (BD) and schizophrenia (SZ). One is PIK3C3, a member of the phosphatidylinositide 3-kinase family that maps closely to markers on 18q linked to both BD and SZ in a few studies.
The promoter region of PIK3C3 was analyzed for mutations by single-strand conformation polymorphism analysis and sequencing. A case-control association study was conducted to determine the distribution of variant alleles in unrelated patients from three cohorts. Electromobility gel shift assays (EMSA) were performed to assess the functional significance of variants.
Two polymorphisms in complete linked disequilibrium with each other were identified, -432C- > T and a "C" insert at position -86. The -432T allele occurs within an octamer containing an ATTT motif resembling members of the POU family of transcription factors. In each population analyzed, an increase in -432T was found in patients. EMSAs showed that a -432T containing oligonucleotide binds to brain proteins that do not recognize -432C.
A promoter mutation in a PI regulator affecting the binding of a POU-type transcription factor may be involved in BD and SZ in a subset of patients.

Download full-text


Available from: Demitri Papolos,
  • Source
    • "Furthermore, a previous study found that IGF-1 and β-NGF produced synergistic effects on neuronal growth via the phosphoinositide 3-kinase (PI3K)-Akt- glycogen synthase kinase-3 (GSK3) pathway (Jones et al., 2003). The PI3K signaling pathway, one of the major intracellular signaling pathways for neurotrophic factors, is associated with the pathophysiology of bipolar disorder and the therapeutic effects of mood stabilizers (Schlecker et al., 2006; Stopkova et al., 2004). Hence, high IGF-1 levels may be the result of disturbed intracellular signaling, such as an over-activated GSK3 pathway that is not appropriately regulated by reciprocal mechanisms. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neurotrophic factors exert substantial effects on the central nervous system. The present study investigates the roles of insulin-like growth factor-1 (IGF-1), β-nerve growth factor (β-NGF), and brain-derived neurotrophic factor (BDNF) in bipolar disorder. Baseline levels of culture-stimulated IGF-1, β-NGF, and BDNF were compared in 116 patients with bipolar I disorder and 123 healthy controls. Neurotrophic factors were also compared in patients before and after 6 weeks of pharmacotherapy. A multivariate logistic regression analysis was used to investigate the influence of the neurotrophic factors analyzed in quartile form, in relation to confounding variables, such as age, sex, and body mass index. IGF-1 was significantly higher in patients (mean=514.57, SD=259.78) than in healthy controls (mean=316.82, SD=270.00, p<0.0001) at baseline. Furthermore, higher levels of IGF-1 substantially increased the risk for bipolar I disorder. IGF-1 level was not significantly changed at 6-weeks (mean=506.41, SD=313.66). No changes in BDNF or β-NGF-1 levels were found following the 6-week treatment period. IGF-1 and β-NGF were negatively correlated in healthy controls, but not in patients. Severity of manic symptoms was not associated with any of the neurotrophic factors. We did not measure cortisol, growth hormone, or IGF-1 receptors. This study is cross-sectional in design. Elevated IGF-1 levels may be a trait marker for bipolar disorder. Further studies are needed to thoroughly investigate the role of IGF-1 in relation to other neuroendocrine factors and biological markers for bipolar disorder.
    Journal of Affective Disorders 08/2013; 151(2). DOI:10.1016/j.jad.2013.07.041 · 3.38 Impact Factor
  • Source
    • "b Treatment-emergent suicidal ideation vs non-treatment-emergent suicidal ideationFB (po0.05). disorder and neurodegeneration (Stopkova et al, 2004; Wang et al, 2011). Hence, nine variants were located in or nearby genes, which were previously linked to bipolar disorder and one variant in a gene also associated with schizophrenia and neurodegeneration. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Emergence of suicidal ideation (TESI) during treatment with antidepressants in major depression led to a black box warning. We performed a genome-wide association study to identify genetic markers, which increase the risk for this serious side effect. TESI was evaluated in depressed in-patients (N=397) and defined by an emergence of suicidal thoughts during hospitalization without suicidal thoughts at admission using the suicide item (3) of the Hamilton Depression Rating Scale. Genotype distribution of 405.383 single-nucleotide polymorphisms (SNPs) in patients with TESI (N=32/8.1%) was compared to patients without increase in suicidal ideation (N=329/82.9%) and to a subgroup never reported suicidal ideation (N=79/19.9%). Top results were analyzed in an independent sample (N=501). None variant reached genome-wide significance, the best associated SNP was rs1630535 (p-value=1.3 × 10(-7)). The top 79 SNPs could be analyzed in an independent sample, and 14 variants showed nominal significant association with the same risk allele in the replication sample. A discriminant analysis classifying patients using these 79 SNPs revealed a 91% probability to classify TESI vs non-TESI cases correctly in the replication sample. Although our data need to be interpreted carefully owing to the small numbers in both cohorts, they suggest that a combination of genetic markers might indeed be used to identify patients at risk for TESI.
    Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 02/2012; 37(3):797-807. DOI:10.1038/npp.2011.257 · 7.05 Impact Factor
  • Source
    • "The implication of genetic factors in SZ and bipolar disorder (BD) is now well established (Craddock et al. 2006). Unsurprisingly, associations between PIK3C3 gene variants in SZ and BD have been reported (Stopkova et al. 2004; Duan et al. 2005; Saito et al. 2005). These studies suggested that PIK3C3 is a putative candidate gene for SZ, BP, and other neurodevelopmental diseases. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Phosphoinositide-3-kinase, class III (PIK3C3) is a member of the phosphoinosite-3-kinases family, involved in cell signaling, membrane trafficking, and neurodevelopment. Previous studies have indeed shown an association between PIK3C3 gene variants and both bipolar disorder (BD) and schizophrenia (SZ). Brain-derived neurotrophic factor (BDNF) is a neurodevelopmental factor, which can regulate the PI3K signaling pathway. Associations have been reported between BDNF gene polymorphisms and affective and psychotic disorders. The aim of the present study was to replicate an association between PIK3C3 and BDNF gene variants in SZ and BD and a putative epistasis between the two genes. Patients meeting the DSM-IV criteria of BD and SZ were included in this study (98 BD and 79 SZ) as well as 158 healthy controls. Blood DNA was extracted and genotyping was performed either by the polymerase chain reaction (PCR) technique followed by enzymatic digestion or by the high-resolution melt (HRM) method. Genotype and haplotype association was assessed with the UNPHASED statistical program.The results showed one nominal association with BD (P < 0.02) and two risk haplotypes in both SZ (P < 0.001) and BP (P < 0.0005), which survived multiple testing correction. A modest interaction between a BDNF variant and PI3KC3 polymorphism was observed (P < 0.04).These preliminary results confirm the genetic association of PI3K gene variants with both SZ and BD, and support the hypothesis that SZ and BD share a genetic background.
    Brain and Behavior 11/2011; 1(2):119-24. DOI:10.1002/brb3.23 · 2.24 Impact Factor
Show more